Leading Biopharmaceuticals Distributor Looks to QlikView for Real-Time Access to Critical Market Data
RALEIGH, NC – October 3, 2005 - FFF Enterprises, the largest U.S. distributor of plasma products and flu vaccine, is using QlikTech to help anticipate and respond to changes in market demand. FFF has deployed QlikView, QlikTech’s innovative business analysis application, to access business information in real time. QlikView enables FFF to enhance efficiency, understand and respond more quickly to changes in the supply chain, and speed the decision-making process.

FFF Enterprises was founded in 1988 and has since grown into a multidimensional healthcare company, delivering innovative solutions in biopharmaceutical distribution, health information management and consumer health services. The company’s mission is to accelerate the availability of lifesaving products and services – from innovation to delivery – with commitment to integrity, safety, and cost containment. Chris Ground, senior vice president of national accounts for FFF Enterprises, has implemented QlikView to help his company carry out its mission faster and more effectively.

“The pharmaceutical industry can change instantly, impacting how, where and what products we bring to market,” said Ground. “It is imperative that people at all levels of our organization have real-time access to the information that affects our business and the delivery of safe, effective products and services. QlikView has given us this capability and fundamentally changed the way we work. We now have immediate access to sales and usage data that used to take hours or even days to compile. QlikView provides us with up-to-the-minute access to vital reports and acts as an early diagnostic tool for the growth of our business.”

QlikView is used for all facets of FFF Enterprises’ business, including finance, sales, operations, IT, and research. Standardizing on QlikView allows all company decision makers to see the same data, so connections can be easily made and management can respond quickly to changes in the market. The ability to see trending issues and analyze these trends from every point in their business has increased FFF’s efficiency, saving the company time and money.

“FFF Enterprises is a visionary in biopharmaceutical distribution and management, and the company recognizes the importance of monitoring and responding to the changing dynamics of its market to stay ahead of the competition,” said Rick Pitts, CEO of QlikTech U.S. “By providing a means for the company to access and analyze business data on the fly, QlikTech is helping FFF Enterprises ensure its current and future success.”

QlikTech is leading a new class of easy to use, fast and flexible business analysis solutions that empower individuals to improve corporate performance and drive innovation. QlikTech’s flagship product, QlikView 7, extends the company’s vision of simplifying business analysis, offering solutions that can be deployed in days, where users can be trained in minutes, and where end users have the freedom to be more creative in their analyses.

About FFF Enterprises
FFF Enterprises was founded in 1988 and has since grown into a multidimensional healthcare company, delivering innovative solutions in biopharmaceutical management and distribution, health information management and consumer healthcare services. FFF is now the nation's largest supplier of human plasma products and flu vaccines, and also distributes other biopharmaceuticals and clinical trial drugs. Customers of FFF's four divisions include members of the leading U.S. acute care and non-acute care group purchasing organizations, pharmaceutical manufacturers, biotech companies, contract research organizations, managed healthcare and consumers. FFF's unique distribution business model has institutionalized Guaranteed Channel Integrity™, which reflects the company's commitment to purchase only from manufacturers and ship only to healthcare providers — one clear line with no gray in between. This protects products from the risks inherent in the secondary and gray markets, while it improves patient safety.

>About QlikTech

<Back to News